Verein für
Association pour le
Associazione per il

medizinische Qualitätskontrolle
contrôle de qualité médical
controllo di qualità medico

Survey Report

2023 - 4

MQ, Institut für Klinische Chemie, Universitätsspital Zürich, 8091 Zürich
Telefon 044/255 34 11, www.MQZH.ch, info@MQZH.ch

Survey Specimens
The homogeneity and stability of all specimens were checked before and/or during shipment and no irregularities were noted. The suitability tests were performed by the laboratories of the Universitätsspital Zürich (University Hospital Zurich) (http://www.uzl.usz.ch/).
The following survey specimens were produced specifically for MQ by a sub-contractor:
B2 Uricult, H4 Parasitic Hematology, K14 tumor marker

Determination of target values

For each target value, the type of determination per ISO17043: 2010 B2.1 is indicated (column "type"):
a Value known due to production.
b Certified reference value for use with special specimens
c Reference value determined by analysis
d Consensus values of expert laboratories
e Consensus values of the participants

For methods groups with more than 9 participants, consensus values of the participants ("e") are generally determined.
In order to calculate the target values, we use the mean value of the method group. Values that differ more than 1.5 times the QUALAB-tolerance are outliers and are not used to calculate the target value. Starting point for the elimination of outliers are the values of our suitability tests.
In order to provide all participants with target values that are as meaningful as possible, other methods may also be applied for smaller method groups.

Uncertainty of the determined target values
The standard uncertainty (u_x) is calculated using the following formula (ISO13528):
ux = (target value/100) * (1.25/square root of "number of participants") * %CV

- ux has the same unit as the target value
- ux can be compared with the standard deviation of the participants' collective (SD=target value*%CV/100)
- For participant numbers >18, the standard uncertainty (ux) is significantly lower than the scatter of the collective participants and can be neglected.

QUALAB and MQ tolerances

For all mandatory analyzes, QUALAB tolerances are used (www.qualab.ch, external quality control). For non-mandatory analyzes, the tolerances are specified by MQ's survey specimen leader.

If the determined uncertainty, ux, of the target value is greater than 15% of the QUALAB or MQ tolerance, the letter indicating the type of target detection is marked with an additional star (example "e*"). Thereby, we are alerting the participants to the fact that the uncertainty of the target value can have an impact on the evaluation.

Graphics
The results are shown graphically as follows:



Comparison of Devices
The data in this report allows you to compare the performance of different devices. However, remember to consider the following:

- The chemical control K1 is a ready-to-use commercial control serum. Even if the specimen is of human origin, it is possible that matrix effects occur. These are device-specific and result in different target values.
- Only one specimen was measured. Since the scatter of the results is dependent on the nature of the specimen (matrix effects) and on the signal strength, the determined coefficient of variations (CV in %) cannot be applied generally.
- A large number of runaways is due to administrative errors (wrong unit, results mixed up) or to operator errors (wrong sample, not correctly taken up in solution, not mixed well) and has nothing to do with the type of device.

.

Zürich, 11.12.2023

Dr. R. Fried
Survey Director

.

INR



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	16	100.0	0.0	0.0	1.53	4.4	e
2	Neoplastin R	16	100.0	0.0	0.0	1.57	3.5	e
3	Neoplastin Plus	7	100.0	0.0	0.0	1.91	5.8	e*
4	STA-NeoPTimal	4	100.0	0.0	0.0	1.67	6.5	e*
5	Recombiplastin 2G	11	100.0	0.0	0.0	1.60	4.9	e
6	Other methods	15	93.3	0.0	6.7	1.57	4.6	e

Fibrinogen OA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	9	100.0	0.0	0.0	1.10	7.4	e*
2	Stago/STA	19	100.0	0.0	0.0	1.16	5.1	e
3	Fibrinogen Q.F.A.	7	100.0	0.0	0.0	1.20	5.0	e*
4	Other methods	5	100.0	0.0	0.0	1.17	7.4	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Activated Prothrombin Time



QUALAB tolerance : 25 %

Activated Prothrombin Time (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	7	100.0	0.0	0.0	37.0	8.0	e*
2	Pathromtin SL	7	100.0	0.0	0.0	62.0	6.3	e
3	Stago/STA	22	100.0	0.0	0.0	49.7	8.1	e
4	aPTT-SP	7	100.0	0.0	0.0	39.6	3.3	e
5	Other methods	11	90.9	9.1	0.0	39.5	13.5	e*

INR CoaguChek



QUALAB tolerance : 15 %

INR CoaguChek ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	803	99.0	0.1	0.9	1.4	2.2	e

Prothrombin time NT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	12	100.0	0.0	0.0	100	0.6	e
2	Neoplastin R	13	100.0	0.0	0.0	95	2.5	e
3	Neoplastin Plus	4	100.0	0.0	0.0	90	5.6	e*
4	STA-NeoPTimal	8	87.5	12.5	0.0	87	7.0	a
5	Recombiplastin 2G	10	100.0	0.0	0.0	100	0.0	e
6	Other methods	15	100.0	0.0	0.0	98	2.5	e

Fibrinogen N



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	8	100.0	0.0	0.0	2.85	4.4	e
2	Stago/STA	19	100.0	0.0	0.0	3.00	4.2	e
3	Fibrinogen Q.F.A.	14	100.0	0.0	0.0	2.90	5.8	e
4	Fib Clauss (IL)	5	100.0	0.0	0.0	2.91	3.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor V



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	94.5	8.7	e*

aPTT N



QUALAB tolerance : 25 %

aPTT N (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	10	100.0	0.0	0.0	22.8	1.9	e
2	Pathromtin SL	5	100.0	0.0	0.0	37.1	5.2	e
3	Stago/STA	21	100.0	0.0	0.0	31.5	6.1	e
4	aPTT-SP	12	100.0	0.0	0.0	25.5	6.8	e
5	Other methods	8	100.0	0.0	0.0	32.6	10.5	e*

Faktor VII



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	97.0	7.6	e*

Prothrombin time HT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	13	100.0	0.0	0.0	100	0.7	e
2	Neoplastin R	13	100.0	0.0	0.0	96	4.0	e
3	Recombiplastin 2G	12	100.0	0.0	0.0	98	2.3	e
4	Other methods	11	100.0	0.0	0.0	96	4.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (unfrakt-Heparin)



MQ tolerance : 20 %

Anti-FXa (unfrakt-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	11	90.9	9.1	0.0	0.27	12.4	e*
2	ACL	22	95.5	4.5	0.0	0.45	10.5	a
3	Other methods	9	100.0	0.0	0.0	0.48	5.5	e

Fibrinogen H



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	4	100.0	0.0	0.0	3.34	3.9	e*
2	Stago/STA	15	100.0	0.0	0.0	3.33	5.7	e
3	Fibrinogen Q.F.A.	14	100.0	0.0	0.0	3.30	6.7	e
4	Other methods	9	100.0	0.0	0.0	3.20	7.7	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

aPTT H



QUALAB tolerance : 25 %

aPTT H (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	4	100.0	0.0	0.0	46.7	7.2	e*
2	Actin FSL	5	100.0	0.0	0.0	48.1	5.5	e
3	Stago/STA	14	100.0	0.0	0.0	77.4	13.0	e*
4	aPTT-SP	16	100.0	0.0	0.0	72.4	6.0	e
5	Other methods	4	100.0	0.0	0.0	46.5	3.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

D-dimer



QUALAB tolerance : 21 %

D-dimer (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas (Zitratplasma)	6	100.0	0.0	0.0	3.07	13.0	e*
2	STA Liatest	17	100.0	0.0	0.0	2.94	5.2	e
3	Siemens Innovance	13	100.0	0.0	0.0	4.82	5.7	e
4	Pathfast	14	100.0	0.0	0.0	5.00	0.0	e
5	ACL	12	100.0	0.0	0.0	4.54	5.9	e
6	AQT 90 FLEX	7	100.0	0.0	0.0	2.16	8.3	e*
7	VIDAS	17	100.0	0.0	0.0	3.41	8.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CoaguChek APTT



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	8	87.5	12.5	0.0	86.2	12.3	e*

INR CCXS



QUALAB tolerance : 15 %

INR CCXS ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek XS	1421	98.8	0.4	0.8	2.0	3.5	e

INR HC



QUALAB tolerance : 15 %

INR HC ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemochron j.	6	66.7	33.3	0.0	1.5	15.8	e*

INR MI



QUALAB tolerance : 15 %

INR MI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MicroINR	139	77.7	5.0	17.3	2.1	8.3	e

INR Xprecia



QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

INR Xprecia ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Xprecia	48	100.0	0.0	0.0	1.2	5.8	e

INR Lumira Dx



INR Lumira Dx ()

QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	11	100.0	0.0	0.0	1.2	4.1	e

Anti-FXa (LMW-Heparin)



MQ tolerance : 20 %

Anti-FXa (LMW-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	9	100.0	0.0	0.0	1.68	5.6	e
2	ACL	15	100.0	0.0	0.0	1.49	4.1	e
3	Other methods	15	100.0	0.0	0.0	1.74	9.2	e

Anti-FXa (Rivaroxaban)



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	9	100.0	0.0	0.0	298.00	5.6	e
2	ACL	8	100.0	0.0	0.0	296.25	8.2	e*
3	Other methods	6	83.3	0.0	16.7	282.30	4.6	e

Anti-FXa (Apixaban)



MQ tolerance : 20 %

Anti-FXa (Apixaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ACL	4	100.0	0.0	0.0	274.70	7.0	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin



QUALAB tolerance : 9 %

Hemoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue Hb 801	5	100.0	0.0	0.0	132.0	1.4	e
2	MEK-1303/5	14	100.0	0.0	0.0	120.0	1.0	e
3	Automat	9	88.9	0.0	11.1	118.0	1.1	e
4	Cyanmethemoglobin	16	93.7	0.0	6.3	118.5	2.0	e
5	Sysmex X	60	100.0	0.0	0.0	118.0	1.5	e
6	Hemocue	399	95.2	2.3	2.5	117.6	2.7	e
7	Hemocontrol	16	100.0	0.0	0.0	118.7	1.8	e
8	DiaSpect	13	100.0	0.0	0.0	124.6	3.5	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex KX21	105	95.2	0.0	4.8	117.8	1.6	e
2	Sysmex PocH - 100i	184	93.5	2.2	4.3	116.1	2.7	e
3	Sysmex XP 300	599	97.2	0.5	2.3	117.6	1.8	e
4	Mythic	234	96.2	0.4	3.4	117.1	2.7	e
5	Sysmex XQ-320	103	97.1	1.0	1.9	118.4	1.7	e
6	Swelab	28	96.4	3.6	0.0	121.8	2.7	e
7	Medonic	4	100.0	0.0	0.0	120.0	1.8	e
8	Celltac Alpha (Nihon	70	92.8	2.9	4.3	120.9	2.8	e
9	Samsung HC10	9	77.8	11.1	11.1	119.0	4.8	e*
10	Micros 60	61	98.4	0.0	1.6	116.2	2.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MEK-1303/5	14	100.0	0.0	0.0	0.39	2.0	e
2	Automat	6	83.3	16.7	0.0	0.31	6.5	e*
3	Sysmex X	60	100.0	0.0	0.0	0.34	2.6	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	104	97.1	0.0	2.9	0.32	2.3	e
2	Sysmex KX21	105	95.2	0.0	4.8	0.32	2.4	e
3	Sysmex PocH - 100i	184	93.5	1.1	5.4	0.34	3.0	e
4	Sysmex XP 300	600	97.7	0.3	2.0	0.32	2.1	e
5	Mythic	234	95.3	1.7	3.0	0.33	3.4	e
6	Swelab	28	96.4	0.0	3.6	0.33	2.6	e
7	Medonic	4	100.0	0.0	0.0	0.32	4.1	e*
8	Celltac Alpha (Nihon	70	88.6	7.1	4.3	0.34	3.9	e
9	Samsung HC10	9	88.9	0.0	11.1	0.33	6.3	e*
10	Micros 60	61	98.4	0.0	1.6	0.31	3.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MEK-1303/5	14	100.0	0.0	0.0	3.85	2.2	e
2	Automat	6	100.0	0.0	0.0	3.67	1.2	e
3	Sysmex X	60	100.0	0.0	0.0	3.69	1.6	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	104	95.2	0.0	4.8	3.80	2.6	e
2	Sysmex KX21	105	97.1	1.0	1.9	3.71	4.5	e
3	Sysmex PocH - 100i	184	95.1	0.0	4.9	3.84	2.7	e
4	Sysmex XP 300	600	98.2	0.3	1.5	3.72	3.0	e
5	Mythic	234	97.9	0.4	1.7	3.67	4.2	e
6	Swelab	28	100.0	0.0	0.0	3.77	3.7	e
7	Medonic	4	100.0	0.0	0.0	3.71	2.3	e
8	Celltac Alpha (Nihon	70	95.7	0.0	4.3	3.81	4.9	e
9	Samsung HC10	9	100.0	0.0	0.0	3.82	11.6	e*
10	Micros 60	61	98.4	0.0	1.6	3.60	3.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MEK-1303/5	14	100.0	0.0	0.0	5.94	5.0	e
2	Automat	5	100.0	0.0	0.0	5.90	11.4	e*
3	Microscopic	5	60.0	20.0	20.0	5.70	21.7	e*
4	Sysmex X	60	100.0	0.0	0.0	5.94	4.6	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

Leucocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	103	98.1	1.9	0.0	5.98	7.6	e
2	Sysmex KX21	105	99.0	1.0	0.0	5.88	6.2	e
3	Sysmex PocH - 100i	184	96.2	0.5	3.3	5.75	6.4	e
4	Sysmex XP 300	600	99.2	0.3	0.5	5.89	5.7	e
5	Mythic	233	98.3	0.4	1.3	5.59	6.7	e
6	Swelab	28	100.0	0.0	0.0	5.77	4.8	e
7	Medonic	4	100.0	0.0	0.0	5.85	5.0	e
8	Celltac Alpha (Nihon	69	95.7	1.4	2.9	5.82	6.3	e
9	Samsung HC10	9	77.8	22.2	0.0	6.22	14.4	e*
10	Micros 60	61	95.1	1.6	3.3	5.32	7.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MEK-1303/5	14	100.0	0.0	0.0	237.1	5.5	e
2	Automat	5	100.0	0.0	0.0	212.0	5.8	e
3	Microscopic	4	75.0	0.0	25.0	234.5	15.5	e*
4	Sysmex X	60	100.0	0.0	0.0	206.3	4.4	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	102	99.0	0.0	1.0	211.1	5.1	e
2	Sysmex KX21	105	98.1	0.0	1.9	213.6	6.0	e
3	Sysmex PocH - 100i	184	97.3	0.0	2.7	217.4	5.9	e
4	Sysmex XP 300	600	99.0	0.5	0.5	215.6	5.9	e
5	Mythic	235	97.5	2.1	0.4	192.8	9.4	e
6	Swelab	28	100.0	0.0	0.0	206.3	8.0	e
7	Medonic	4	100.0	0.0	0.0	200.0	3.6	e
8	Celltac Alpha (Nihon	70	97.1	2.9	0.0	227.1	9.7	e
9	Samsung HC10	9	88.9	0.0	11.1	244.0	15.6	e*
10	Micros 60	60	98.3	0.0	1.7	195.9	8.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	219	95.0	0.9	4.1	103.1	3.3	e
2	Abx Micros	50	96.0	0.0	4.0	102.9	3.1	e
3	Microsemi	895	97.5	0.7	1.8	104.1	2.0	e

Hematocrit H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	219	92.2	3.7	4.1	0.30	4.2	e
2	Abx Micros	50	92.0	4.0	4.0	0.27	3.9	e
3	Microsemi	895	97.1	0.6	2.3	0.28	2.6	e

Leucocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	219	99.0	0.5	0.5	5.56	5.6	e
2	Abx Micros	50	98.0	0.0	2.0	5.58	5.5	e
3	Microsemi	895	99.3	0.3	0.4	5.74	4.8	e

Thrombocytes H2



QUALAB tolerance : 25 %

Thrombocytes H2 (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	219	98.2	0.9	0.9	192.8	7.2	e
2	Abx Micros	50	90.0	4.0	6.0	193.4	9.3	e
3	Microsemi	894	98.5	0.4	1.1	195.0	7.0	e

Erythrocytes H2



QUALAB tolerance : 25 %

Erythrocytes H2 (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	219	96.4	0.9	2.7	3.23	5.1	e
2	Abx Micros	50	96.0	2.0	2.0	3.20	6.2	e
3	Microsemi	894	98.8	0.2	1.0	3.22	3.4	e

CRP H2



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	203	90.2	4.4	5.4	47.0	10.0	e
2	Microsemi	877	93.6	2.9	3.5	67.1	8.9	e
3	Abx Micros	12	83.3	0.0	16.7	67.7	5.5	e
4	ABX Micros CRP200	38	94.7	0.0	5.3	61.9	11.0	e

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	12	100.0	0.0	0.0	117.7	3.0	e

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	18	100.0	0.0	0.0	0.35	3.4	e
2	EPOC	13	92.3	0.0	7.7	0.36	2.2	e

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	110	100.0	0.0	0.0	118.2	1.4	e
2	Advia	4	100.0	0.0	0.0	121.0	1.7	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	119.9	1.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	112	100.0	0.0	0.0	0.36	2.9	a
2	Advia	4	100.0	0.0	0.0	0.37	2.7	e*
3	Yumizen/Pentra	13	100.0	0.0	0.0	0.34	3.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	111	100.0	0.0	0.0	3.87	1.8	e
2	Advia	4	100.0	0.0	0.0	3.96	2.0	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	3.86	2.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	111	99.1	0.9	0.0	4.75	7.1	e
2	Advia	4	100.0	0.0	0.0	4.70	2.2	e
3	Yumizen/Pentra	13	76.9	15.4	7.7	3.73	19.2	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	110	100.0	0.0	0.0	163.7	4.5	e
2	Advia	4	100.0	0.0	0.0	147.5	4.4	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	162.4	4.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Neutrophils



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	112	100.0	0.0	0.0	2.69	9.7	a
2	Advia	4	100.0	0.0	0.0	2.77	4.0	a
3	Yumizen/Pentra	12	100.0	0.0	0.0	1.28	22.0	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lymphocytes



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	112	100.0	0.0	0.0	1.61	7.8	a
2	Advia	4	100.0	0.0	0.0	1.45	3.8	a
3	Yumizen/Pentra	12	100.0	0.0	0.0	1.64	20.2	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Monocytes



MQ tolerance : 40 %

Monocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	111	100.0	0.0	0.0	0.29	26.4	a
2	Advia	4	100.0	0.0	0.0	0.28	15.3	a
3	Yumizen/Pentra	12	91.7	0.0	8.3	0.18	39.0	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Eosinophils



MQ tolerance : 80 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	111	100.0	0.0	0.0	0.04	33.5	a
2	Advia	4	100.0	0.0	0.0	0.07	6.9	e
3	Yumizen/Pentra	12	100.0	0.0	0.0	0.02	46.7	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Basophiles



MQ tolerance : 80 %
(< 0.10: +/- 0.08 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	112	100.0	0.0	0.0	0.13	66.1	a
2	Advia	4	100.0	0.0	0.0	0.02	66.7	e*
3	Yumizen/Pentra	12	91.7	8.3	0.0	0.05	62.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCV



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	101	100.0	0.0	0.0	91.4	3.1	e
2	Yumizen/Pentra	9	100.0	0.0	0.0	90.0	1.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

MCH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	101	100.0	0.0	0.0	30.5	1.4	e
2	Yumizen/Pentra	10	100.0	0.0	0.0	31.1	3.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

MCHC



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	102	99.0	0.0	1.0	334	3.1	e
2	Yumizen/Pentra	10	100.0	0.0	0.0	349	3.6	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

RDW



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	98	100.0	0.0	0.0	12.4	3.3	e
2	Yumizen/Pentra	9	100.0	0.0	0.0	13.7	8.2	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Immature Granulocytes



MQ tolerance : 25 %
(< 0.10: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	94	91.5	6.4	2.1	0.07	43.1	a

Reticulocytes



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	62	96.8	3.2	0.0	61.4	14.2	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Hämolyseindex Probe A



MQ tolerance : 30 %

Hämolyseindex Probe A ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	24	95.8	0.0	4.2	24.52	8.6	e
2	Abbott	6	100.0	0.0	0.0	0.18	7.9	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Hämolyseindex Probe B



MQ tolerance : 30 %

Hämolyseindex Probe B ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	24	91.7	0.0	8.3	12.50	7.7	e
2	Abbott	6	100.0	0.0	0.0	0.09	9.4	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipemia index A



MQ tolerance : 30 %

Lipemia index A ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	100.0	0.0	0.0	34.50	9.1	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lipemia index B



MQ tolerance : 30 %

Lipemia index B ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	83.3	0.0	16.7	15.00	9.8	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Icteria Index A



MQ tolerance : 30 %

Icteria Index A ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	100.0	0.0	0.0	7.00	0.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Icteria Index B



MQ tolerance : 30 %
(< 5.00: +/- 1.50)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	83.3	0.0	16.7	3.00	0.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocyte sedimentation rate 1h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 1h (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MINI-CUBE	24	100.0	0.0	0.0	13	25.8	a
2	miniiSed	8	100.0	0.0	0.0	1	0.0	a
3	Sarstedt Sedivette	19	100.0	0.0	0.0	9	25.5	a
4	Sarstedt Microvette	4	100.0	0.0	0.0	11	8.9	a
5	BD Seditainer	42	95.2	0.0	4.8	9	22.5	a
6	Other methods	19	89.5	0.0	10.5	10	26.3	a

Erythrocyte sedimentation rate 2h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 2h (mm/2h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sarstedt Sedivette	7	100.0	0.0	0.0	19	25.0	a
2	BD Seditainer	4	75.0	0.0	25.0	19	3.1	a
3	Other methods	4	100.0	0.0	0.0	20	21.1	e*

Hemoglobin HS



MQ tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	17	94.1	5.9	0.0	155.4	4.3	e

Hematocrit HS



MQ tolerance : 9 %

Hematocrit HS (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	17	94.1	5.9	0.0	0.4	4.9	e*

Erythrocytes HS



MQ tolerance : 25 %

Erythrocytes HS (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	17	100.0	0.0	0.0	4.49	4.4	e

Leucocytes HS



MQ tolerance : 25 %

Leucocytes HS (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	17	100.0	0.0	0.0	7.97	8.1	e

Trombocytes HS



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	17	100.0	0.0	0.0	240.2	5.4	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	10	80.0	0.0	20.0	54.1	5.2	e
2	Cobas b101	400	99.2	0.0	0.8	47.0	4.7	e
3	Cobas	37	97.3	2.7	0.0	52.9	6.6	e
4	Turbidimetry	5	100.0	0.0	0.0	60.2	6.1	e*
5	Afinion	1103	99.2	0.3	0.5	52.7	5.0	e
6	NycoCard SingleTest-	61	80.3	3.3	16.4	50.0	9.9	e
7	Quick Read go	83	96.4	1.2	2.4	56.7	8.2	e
8	Eurolyser	70	60.0	11.4	28.6	66.9	14.1	e
9	Fuji Dri-Chem	14	78.6	7.1	14.3	55.6	8.2	e
10	Piccolo	4	100.0	0.0	0.0	77.0	3.1	e
11	Celltac chemi	43	100.0	0.0	0.0	54.0	7.7	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	QuikRead (Vollblut)	21	95.2	4.8	0.0	90.9	8.1	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Spinit	15	100.0	0.0	0.0	46.2	7.9	e
2	Abbott	14	100.0	0.0	0.0	55.4	5.8	e
3	AQT 90 FLEX	7	100.0	0.0	0.0	57.0	4.9	e
4	Spotchem D-Concept	6	100.0	0.0	0.0	56.3	5.0	e
5	Other methods	6	100.0	0.0	0.0	54.0	7.7	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

IgG



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	21	100.0	0.0	0.0	10.76	3.9	e
2	Nephelometry	4	100.0	0.0	0.0	10.75	3.7	e*
3	Other methods	5	100.0	0.0	0.0	10.90	2.4	e

IgA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	19	100.0	0.0	0.0	1.73	4.7	e
2	Nephelometry	5	100.0	0.0	0.0	1.91	4.0	e
3	Other methods	4	100.0	0.0	0.0	1.68	10.4	e*

IgM



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	20	95.0	0.0	5.0	0.83	4.7	e
2	Nephelometry	5	100.0	0.0	0.0	0.84	4.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IgE



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	76	11.2	e*
2	Cobas	6	100.0	0.0	0.0	95	4.4	e

Alpha-1-Antitrypsin



MQ tolerance : 25 %

Alpha-1-Antitrypsin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	1.21	5.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-Streptolysin-Antibodies



MQ tolerance : 25 %

Anti-Streptolysin-Antibodies (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	92.3	0.0	7.7	121	5.1	e
2	Other methods	6	100.0	0.0	0.0	84	4.4	e

Complement C3



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	100.0	0.0	0.0	1.38	3.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Complement C4



QUALAB tolerance : 15 %

Complement C4 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	5	100.0	0.0	0.0	0.25	5.4	e*
2	Other methods	15	100.0	0.0	0.0	0.24	9.4	e*

Haptoglobin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	29	100.0	0.0	0.0	1.17	3.0	e

Transferrin



MQ tolerance : 25 %

Transferrin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	34	100.0	0.0	0.0	2.23	2.5	e

Beta-2 microglobuline



MQ tolerance : 25 %

Beta-2 microglobuline (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	1.53	6.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Rheumatoid factor



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Architect	6	100.0	0.0	0.0	29.7	5.8	e
2	Other methods	6	100.0	0.0	0.0	30.0	4.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Ceruloplasmin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	8	100.0	0.0	0.0	302.50	2.1	e
2	Other methods	4	100.0	0.0	0.0	220.00	1.1	e

Prealbumin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	199.94	6.2	e

Soluble transferrin receptor



MQ tolerance : 25 %

Soluble transferrin receptor (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	100.0	0.0	0.0	2.2	3.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

free light chain kappa



QUALAB tolerance : 20 %

free light chain kappa (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	7.84	4.9	e
2	Freelite	12	100.0	0.0	0.0	14.46	7.4	e

free light chain lambda



QUALAB tolerance : 20 %

free light chain lambda (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	7.34	4.7	e
2	Freelite	12	91.7	8.3	0.0	12.48	9.3	e*

IgE peanut qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	100.0	0.0	0.0	0.37	22.7	e*

IgE birch qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	100.0	0.0	0.0	0.19	28.9	e*

IgE cat qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	1.04	10.3	e

IgE total



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	258	8.0	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

IgE sx1 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	13.67	12.2	e*

IgE fx5 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	11	90.9	0.0	9.1	2.01	13.9	e*

IgE rx1qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	0.44	7.2	e

IgE rx2 qn



MQ tolerance : 30 %

IgE rx2 qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	9.26	5.3	e

IgE D. pteronyssinus qn



QUALAB tolerance : 30 %

IgE D. pteronyssinus qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	15.94	10.2	e

CRP HS



QUALAB tolerance : 21 %
(< 10.00: +/- 2.00 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	10	100.0	0.0	0.0	5.52	11.8	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipoprotein (a)



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	56	8.5	e*
2	Others	4	100.0	0.0	0.0	69	5.0	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	158	91.1	1.9	7.0	69.2	8.5	e

Anti deam. Gliadin IgA



MQ tolerance : 30 %

Anti deam. Gliadin IgA (U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	3.30	7.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti tTG IgG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	37.00	7.7	e*

Anti tTG IgA



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	6	100.0	0.0	0.0	109.50	8.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP Lumira



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	13	76.9	7.7	15.4	180.4	14.8	e*

Albumine



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hitachi S40/M40	4	100.0	0.0	0.0	30.5	2.0	e
2	Abbott	10	100.0	0.0	0.0	36.4	2.7	e
3	Autolyser	8	100.0	0.0	0.0	37.5	2.3	e
4	Beckman	4	100.0	0.0	0.0	37.0	2.6	e
5	Fuji Dri-Chem	236	98.8	0.8	0.4	46.2	3.9	e
6	Piccolo	60	96.6	1.7	1.7	39.4	5.0	e
7	Roche	29	100.0	0.0	0.0	38.1	3.4	e
8	Selectra Pro	11	100.0	0.0	0.0	36.1	3.5	e
9	Siemens	5	100.0	0.0	0.0	37.0	5.4	e*
10	Skyla	5	100.0	0.0	0.0	37.0	3.0	e
11	Spotchem D-Concept	233	98.3	1.3	0.4	45.6	4.7	e
12	Spotchem SP-4430	31	100.0	0.0	0.0	41.2	4.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Alkaline phosphatase



QUALAB tolerance : 18 %

Alkaline phosphatase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	92.9	0.0	7.1	92	3.0	e
2	Autolyser	21	100.0	0.0	0.0	83	6.7	e
3	Beckman	6	100.0	0.0	0.0	95	3.0	e
4	Fuji Dri-Chem	1020	98.0	1.2	0.8	94	7.0	e
5	Piccolo	52	98.1	0.0	1.9	100	5.3	e
6	Roche	29	100.0	0.0	0.0	82	5.0	e
7	Selectra Pro	15	100.0	0.0	0.0	96	7.8	e
8	Siemens	6	100.0	0.0	0.0	81	4.0	e
9	Skyla	5	100.0	0.0	0.0	97	5.0	e*
10	Spotchem D-Concept	540	98.9	0.0	1.1	81	5.3	e
11	Spotchem SP-4430	93	93.5	5.4	1.1	67	8.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Amylase



QUALAB tolerance : 18 %
(< 50: +/- 9 U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	7	100.0	0.0	0.0	115	4.1	e
2	Autolyser	8	87.5	12.5	0.0	115	8.3	e*
3	Beckman	4	100.0	0.0	0.0	143	3.4	e
4	Fuji Dri-Chem	742	98.7	0.4	0.9	90	5.0	e
5	Piccolo	52	98.1	0.0	1.9	122	3.7	e
6	Roche	8	100.0	0.0	0.0	133	2.6	e
7	Selectra Pro	9	88.9	11.1	0.0	175	8.9	e*
8	Spotchem D-Concept	397	95.0	3.0	2.0	63	7.7	e
9	Spotchem SP-4430	61	93.4	6.6	0.0	22	23.8	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Pancreatic amylase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	93	5.2	e
2	Autolyser	11	100.0	0.0	0.0	100	4.2	e
3	Roche	14	100.0	0.0	0.0	109	3.0	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	25.4	9.6	e*
2	Autolyser	18	100.0	0.0	0.0	22.1	3.7	e
3	Beckman	6	83.3	0.0	16.7	31.3	5.0	e
4	Fuji Dri-Chem	827	96.7	1.7	1.6	28.0	7.8	e
5	Piccolo	58	89.6	5.2	5.2	25.0	8.0	e
6	Reflotron	4	100.0	0.0	0.0	24.8	10.7	e*
7	Roche	28	100.0	0.0	0.0	24.1	5.2	e
8	Selectra Pro	15	66.7	20.0	13.3	18.5	14.9	e*
9	Siemens	6	100.0	0.0	0.0	30.2	6.5	e*
10	Skyla	5	100.0	0.0	0.0	31.8	1.8	e
11	Spotchem D-Concept	426	98.1	1.4	0.5	23.3	7.2	e
12	Spotchem SP-4430	82	92.7	2.4	4.9	29.0	9.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Bilirubin direct



MQ tolerance : 18 %

Bilirubin direct (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	8	100.0	0.0	0.0	18.5	4.1	e
2	Fuji Dri-Chem	21	85.7	14.3	0.0	14.1	11.0	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium



QUALAB tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	5	100.0	0.0	0.0	2.02	1.9	e
2	Siemens	6	100.0	0.0	0.0	1.98	4.2	e*
3	Abbott	14	100.0	0.0	0.0	1.99	2.1	e
4	Autolyser	9	100.0	0.0	0.0	2.07	4.2	e*
5	Fuji Dri-Chem	296	96.3	2.0	1.7	2.04	4.0	e
6	Piccolo	51	96.1	3.9	0.0	1.99	3.1	e
7	Roche	29	100.0	0.0	0.0	1.99	1.9	e
8	Selectra Pro	6	100.0	0.0	0.0	2.00	2.7	e*
9	Spotchem D-Concept	78	97.4	0.0	2.6	1.42	5.5	e
10	Spotchem SP-4430	15	73.3	26.7	0.0	1.79	7.7	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium ISE



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	7	85.7	14.3	0.0	0.77	7.4	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Chloride



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	105	1.6	e
2	Beckman	5	100.0	0.0	0.0	102	0.8	e
3	Fuji Dri-Chem	933	97.3	1.3	1.4	110	1.9	e
4	Piccolo	27	100.0	0.0	0.0	105	1.2	e
5	Roche	20	90.0	5.0	5.0	103	2.1	e
6	Siemens	6	100.0	0.0	0.0	106	0.8	e
7	Spotchem D-Concept	427	97.7	1.6	0.7	113	2.2	e
8	Spotchem EL-SE 1520	76	89.5	9.2	1.3	118	3.5	e
9	iStat Chem8	7	100.0	0.0	0.0	112	1.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total



QUALAB tolerance : 10 %

Cholesterol total (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	4	100.0	0.0	0.0	4.43	1.1	e
2	Siemens	5	100.0	0.0	0.0	4.20	3.0	e*
3	Abbott	15	100.0	0.0	0.0	4.27	2.6	e
4	Autolyser	21	95.2	0.0	4.8	4.15	3.4	e
5	Fuji Dri-Chem	975	96.1	2.1	1.8	3.93	4.3	e
6	Piccolo	29	96.6	0.0	3.4	4.14	1.9	e
7	Reflotron	8	87.5	12.5	0.0	3.90	5.3	e*
8	Roche	27	100.0	0.0	0.0	4.19	2.3	e
9	Selectra Pro	14	92.9	7.1	0.0	4.26	5.4	e*
10	Spotchem D-Concept	452	96.7	1.5	1.8	4.17	3.9	e
11	Spotchem SP-4430	89	96.7	1.1	2.2	4.00	3.4	e
12	Cholestech LDX	280	96.4	1.1	2.5	4.27	3.7	e
13	Other methods	4	100.0	0.0	0.0	3.55	5.3	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterin HDL



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	4	100.0	0.0	0.0	1.72	6.8	e*
2	Abbott	14	100.0	0.0	0.0	1.01	3.9	e
3	Autolyser	21	100.0	0.0	0.0	1.66	6.1	e
4	Beckman	8	100.0	0.0	0.0	1.18	11.3	a
5	Fuji Dri-Chem	940	98.5	0.1	1.4	1.48	3.4	e
6	Piccolo	29	100.0	0.0	0.0	1.10	8.0	e
7	Roche	24	95.8	4.2	0.0	0.97	6.7	e
8	Selectra Pro	14	85.7	0.0	14.3	1.76	11.9	e*
9	Spotchem D-Concept	435	92.6	5.1	2.3	0.79	10.5	e
10	Spotchem SP-4430	80	94.9	3.8	1.3	0.72	9.3	e
11	Cholestech LDX	280	91.4	5.4	3.2	1.06	9.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatine kinase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	5	100.0	0.0	0.0	173	2.7	e
2	Abbott	14	100.0	0.0	0.0	173	2.0	e
3	Autolyser	18	100.0	0.0	0.0	185	3.8	e
4	Fuji Dri-Chem	658	98.0	0.5	1.5	181	5.0	e
5	Piccolo	18	100.0	0.0	0.0	174	3.6	e
6	Roche	26	100.0	0.0	0.0	166	2.1	e
7	Selectra Pro	10	100.0	0.0	0.0	174	4.7	e
8	Siemens	6	100.0	0.0	0.0	160	1.5	e
9	Spotchem D-Concept	319	98.8	0.3	0.9	150	6.3	e
10	Spotchem SP-4430	45	100.0	0.0	0.0	155	8.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol LDL



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	10	80.0	0.0	20.0	2.7	5.5	e
2	Selectra	4	75.0	0.0	25.0	2.7	4.4	e*
3	Standard chemistry	14	100.0	0.0	0.0	2.1	3.3	e
4	Roche, Cobas	15	100.0	0.0	0.0	2.8	3.3	e
5	Beckman	4	100.0	0.0	0.0	2.8	3.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Iron



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	11	100.0	0.0	0.0	37	2.4	e
2	Roche	19	100.0	0.0	0.0	37	1.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Gamma-glutamyltransferase



QUALAB tolerance : 18 %
(< 40: +/- 8 U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	42	4.3	e
2	Cobas	30	96.7	3.3	0.0	38	7.1	e
3	Autolyser	21	100.0	0.0	0.0	39	4.3	e
4	Beckman	6	100.0	0.0	0.0	40	2.0	e
5	Fuji Dri-Chem	1128	98.4	0.2	1.4	47	5.3	e
6	Piccolo	56	100.0	0.0	0.0	36	5.6	e
7	Reflotron	13	84.6	15.4	0.0	47	10.5	e*
8	Selectra Pro	15	100.0	0.0	0.0	37	7.8	e
9	Siemens	5	100.0	0.0	0.0	43	6.0	e*
10	Skyla	5	100.0	0.0	0.0	43	8.5	e*
11	Spotchem D-Concept	613	97.9	1.0	1.1	44	6.1	e
12	Spotchem SP-4430	135	98.5	1.5	0.0	47	6.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	6.1	1.6	e
2	Autolyser	19	78.9	15.8	5.3	6.1	6.1	e*
3	Fuji Dri-Chem	1066	98.8	0.4	0.8	5.8	2.4	e
4	Piccolo	68	100.0	0.0	0.0	6.2	1.3	e
5	Reflotron	12	91.7	8.3	0.0	5.9	5.2	e*
6	Roche	30	100.0	0.0	0.0	6.1	1.8	e
7	Selectra Pro	16	93.7	0.0	6.3	6.3	3.4	e
8	Siemens	6	100.0	0.0	0.0	6.4	3.1	e*
9	Spotchem D-Concept	575	96.5	3.5	0.0	6.1	4.3	e
10	Spotchem SP-4430	118	95.8	2.5	1.7	6.3	3.5	e
11	iStat Chem8	8	100.0	0.0	0.0	5.7	2.3	e
12	Cholestech LDX	277	97.8	0.4	1.8	5.8	3.1	e
13	Cobas Pulse	11	100.0	0.0	0.0	5.6	3.0	e
14	Beckman	6	100.0	0.0	0.0	6.2	4.1	e*

4 additional results were submitted but not published because the method-groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Accu-Chek Instant	117	98.2	0.9	0.9	5.7	3.3	e
2	Accu-Chek Aviva	125	86.4	8.8	4.8	6.4	4.5	e
3	Accu-Chek Inform 2	917	98.4	0.9	0.7	6.9	3.0	e
4	Accu-Check Guide	331	95.5	2.1	2.4	5.6	3.8	e
5	Contour XT	1409	95.1	4.0	0.9	6.1	4.3	e
6	Skyla	5	100.0	0.0	0.0	6.3	1.7	e
7	Statstrip/Xpress	92	98.9	1.1	0.0	5.9	4.1	e
8	Glucocard	9	88.9	11.1	0.0	8.3	6.3	e*
9	Hemocue 201+ P-equiv	118	95.8	1.7	2.5	7.7	3.6	e
10	Hemocue 201RT P-equi	131	98.5	0.0	1.5	7.7	2.5	e
11	CardioChek	4	50.0	25.0	25.0	8.0	6.1	e*
12	Freestyle Freedom li	4	100.0	0.0	0.0	6.4	1.6	e
13	Contour NEXT	42	90.5	2.4	7.1	5.8	3.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue 201+ (alt)	31	96.8	3.2	0.0	7.6	3.3	e
2	OneTouch Verio	24	95.8	4.2	0.0	6.0	3.6	e
3	Contour 2 (5s)	8	87.5	12.5	0.0	4.9	5.8	e*
4	Healthpro	22	81.9	13.6	4.5	10.2	6.3	e*
5	Mylife UNIO	441	98.1	1.4	0.5	7.3	3.6	e
6	mylife Pura	104	95.2	2.9	1.9	6.7	4.3	e
7	Alpha Check	10	90.0	0.0	10.0	9.2	4.9	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Uric Acid



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	272	2.8	e
2	Autolyser	19	94.7	5.3	0.0	278	6.1	e
3	Beckman	6	100.0	0.0	0.0	280	3.4	e
4	Fuji Dri-Chem	1048	98.7	0.4	0.9	309	2.6	e
5	Piccolo	36	86.1	5.6	8.3	203	7.3	e
6	Roche	27	100.0	0.0	0.0	269	2.8	e
7	Selectra Pro	16	100.0	0.0	0.0	264	3.8	e
8	Siemens	6	100.0	0.0	0.0	272	2.9	e
9	Reflotron	7	100.0	0.0	0.0	298	5.0	e*
10	Skyla	5	100.0	0.0	0.0	276	4.8	e*
11	Spotchem D-Concept	571	97.9	0.5	1.6	257	4.2	e
12	Spotchem SP-4430	115	96.6	1.7	1.7	234	5.1	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Urea



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	7.7	6.8	e*
2	Autolyser	15	100.0	0.0	0.0	7.8	7.5	e*
3	Beckman	8	100.0	0.0	0.0	7.4	3.0	e
4	Fuji Dri-Chem	629	99.2	0.2	0.6	7.5	2.6	e
5	Piccolo	61	100.0	0.0	0.0	6.5	2.7	e
6	Reflotron	5	100.0	0.0	0.0	7.5	3.6	e
7	Roche	27	100.0	0.0	0.0	7.2	2.8	e
8	Selectra Pro	12	100.0	0.0	0.0	7.5	5.8	e
9	Siemens	7	100.0	0.0	0.0	7.6	3.9	e
10	Skyla	5	100.0	0.0	0.0	7.5	2.9	e
11	Spotchem D-Concept	328	96.1	3.0	0.9	6.8	7.3	e
12	Spotchem SP-4430	60	93.3	5.0	1.7	6.7	6.9	e
13	iStat Chem8	9	88.9	0.0	11.1	9.8	3.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Potassium



QUALAB tolerance : 6 %
(< 3.30: +/- 0.20 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	3.01	0.9	e
2	Autolyser	20	85.0	10.0	5.0	2.82	5.2	e*
3	Beckman	6	100.0	0.0	0.0	3.00	1.4	e
4	Fuji Dri-Chem	1102	94.7	3.6	1.7	3.00	2.1	e
5	Piccolo	39	59.0	33.3	7.7	3.20	4.8	e*
6	Roche	29	100.0	0.0	0.0	3.03	1.4	e
7	Siemens	6	100.0	0.0	0.0	3.00	1.7	e
8	Reflotron	9	44.5	11.1	44.4	3.30	3.9	e*
9	Spotchem D-Concept	546	98.2	0.0	1.8	2.73	2.4	e
10	Spotchem EL-SE 1520	100	96.0	2.0	2.0	2.72	3.0	e
11	iStat Chem8	11	100.0	0.0	0.0	2.97	2.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	177	3.6	e
2	Autolyser	21	100.0	0.0	0.0	169	3.8	e
3	Beckman	6	100.0	0.0	0.0	179	3.3	e
4	Fuji Dri-Chem	1159	98.9	0.3	0.8	161	4.4	e
5	Piccolo	65	100.0	0.0	0.0	178	6.6	e
6	Reflotron	23	95.7	0.0	4.3	188	7.4	e
7	Roche	30	100.0	0.0	0.0	175	3.7	e
8	Selectra Pro	16	100.0	0.0	0.0	166	5.4	e
9	Siemens	6	100.0	0.0	0.0	179	3.5	e
10	Skyla	5	100.0	0.0	0.0	161	3.7	e
11	Spotchem D-Concept	621	98.4	0.3	1.3	81	5.4	e
12	Spotchem SP-4430	158	98.7	1.3	0.0	79	6.2	e
13	EPOC	11	63.6	0.0	36.4	174	5.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine E



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	37	100.0	0.0	0.0	173	3.0	e
2	ABL700/800	13	92.3	0.0	7.7	178	5.4	e

eGFR CKD-EPI



MQ tolerance : 30 %

eGFR CKD-EPI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	55	96.4	3.6	0.0	40	10.2	e
2	Reflotron	8	87.5	0.0	12.5	40	12.3	e*
3	Fuji Dri-Chem	407	96.0	2.0	2.0	45	7.9	e
4	Spotchem	281	96.5	2.1	1.4	104	8.6	e

eGFR Cockcroft-Gault



MQ tolerance : 30 %

eGFR Cockcroft-Gault ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	39	97.4	0.0	2.6	49	11.3	e
2	Spotchem	14	100.0	0.0	0.0	108	7.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

eGFR MDRD



MQ tolerance : 30 %

eGFR MDRD ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	4	75.0	0.0	25.0	48	3.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

LDH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	129	4.7	e
2	Autolyser	7	85.7	14.3	0.0	135	12.1	e*
3	Beckman	4	100.0	0.0	0.0	132	2.7	e
4	Fuji Dri-Chem	117	98.3	0.0	1.7	114	4.6	e
5	Piccolo	4	100.0	0.0	0.0	110	2.4	e
6	Roche	27	100.0	0.0	0.0	137	2.3	e
7	Siemens	5	100.0	0.0	0.0	138	6.8	e*
8	Spotchem D-Concept	42	71.4	11.9	16.7	71	13.2	e
9	Spotchem SP-4430	14	85.7	14.3	0.0	69	12.8	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Magnesium



QUALAB tolerance : 12 %
(< 0.70: +/- 0.09 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Spotchem SP-4430	5	100.0	0.0	0.0	0.55	3.0	e
2	Abbott	13	100.0	0.0	0.0	0.63	2.9	e
3	Beckman	5	100.0	0.0	0.0	0.66	2.8	e
4	Fuji Dri-Chem	76	94.8	2.6	2.6	0.70	3.8	e
5	Piccolo	4	100.0	0.0	0.0	0.65	4.5	e*
6	Roche	22	100.0	0.0	0.0	0.64	2.7	e
7	Siemens	5	100.0	0.0	0.0	0.63	5.1	e*
8	Spotchem D-Concept	36	100.0	0.0	0.0	0.48	5.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	9	100.0	0.0	0.0	147	0.9	e
2	Abbott	15	100.0	0.0	0.0	144	0.8	e
3	Beckman	6	100.0	0.0	0.0	142	1.1	e
4	Fuji Dri-Chem	1012	97.9	0.8	1.3	146	1.4	e
5	Roche	29	100.0	0.0	0.0	143	0.7	e
6	Siemens	6	100.0	0.0	0.0	144	1.8	e*
7	Spotchem D-Concept	475	99.8	0.0	0.2	139	1.4	e
8	Spotchem EL-SE 1520	84	100.0	0.0	0.0	139	2.0	e
9	Piccolo	37	97.3	0.0	2.7	140	2.1	e
10	iStat Chem8	10	100.0	0.0	0.0	143	0.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Phosphate



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	1.1	3.8	e
2	Beckman	4	100.0	0.0	0.0	1.1	3.3	e
3	Fuji Dri-Chem	75	96.0	1.3	2.7	1.1	5.8	e
4	Piccolo	6	83.3	16.7	0.0	1.4	6.6	e*
5	Roche	25	96.0	4.0	0.0	1.1	4.0	e
6	Siemens	9	100.0	0.0	0.0	1.1	3.6	e
7	Spotchem D-Concept	14	100.0	0.0	0.0	1.2	2.9	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

Protein total



QUALAB tolerance : 12 %

Protein total (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	57.6	4.1	e
2	Beckman	4	100.0	0.0	0.0	58.0	0.8	e
3	Fuji Dri-Chem	189	97.3	1.1	1.6	55.8	3.5	e
4	Piccolo	49	95.9	0.0	4.1	58.8	1.5	e
5	Roche	25	100.0	0.0	0.0	58.6	3.0	e
6	Selectra Pro	8	87.5	0.0	12.5	57.3	4.9	e*
7	Siemens	6	100.0	0.0	0.0	61.0	2.9	e
8	Skyla	5	100.0	0.0	0.0	62.0	1.8	e
9	Spotchem D-Concept	187	95.2	2.7	2.1	55.0	5.1	e
10	Spotchem SP-4430	27	92.6	7.4	0.0	60.3	6.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Aspartate aminotransferase



QUALAB tolerance : 18 %

Aspartate aminotransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	72	4.2	e
2	Autolyser	21	100.0	0.0	0.0	66	4.9	e
3	Beckman	6	100.0	0.0	0.0	73	2.5	e
4	Fuji Dri-Chem	1138	98.3	1.2	0.5	68	4.9	e
5	Piccolo	71	97.2	2.8	0.0	65	5.9	e
6	Reflotron	17	76.5	5.9	17.6	85	9.5	e*
7	Roche	30	100.0	0.0	0.0	71	4.2	e
8	Selectra Pro	16	100.0	0.0	0.0	73	4.5	e
9	Siemens	6	100.0	0.0	0.0	70	4.8	e
10	Skyla	5	100.0	0.0	0.0	70	2.0	e
11	Spotchem D-Concept	613	98.8	0.5	0.7	43	5.1	e
12	Spotchem SP-4430	147	98.6	1.4	0.0	40	6.0	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Alanine aminotransferase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	50	5.7	e
2	Autolyser	21	100.0	0.0	0.0	55	4.6	e
3	Beckman	6	100.0	0.0	0.0	58	2.1	e
4	Fuji Dri-Chem	1151	97.8	0.9	1.3	60	5.8	e
5	Piccolo	69	97.1	0.0	2.9	54	5.3	e
6	Reflotron	12	83.3	16.7	0.0	50	12.1	e*
7	Roche	30	100.0	0.0	0.0	56	2.8	e
8	Selectra Pro	16	87.4	6.3	6.3	62	9.8	e*
9	Siemens	6	100.0	0.0	0.0	60	2.2	e
10	Skyla	5	100.0	0.0	0.0	60	3.2	e
11	Spotchem D-Concept	620	94.8	4.2	1.0	36	8.0	e
12	Spotchem SP-4430	150	88.6	8.7	2.7	35	9.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Triglycerides



QUALAB tolerance : 18 %

Triglycerides (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	4	100.0	0.0	0.0	2.36	2.3	e
2	Abbott	13	100.0	0.0	0.0	2.21	2.0	e
3	Autolyser	21	100.0	0.0	0.0	2.13	5.9	e
4	Fuji Dri-Chem	957	98.8	0.2	1.0	2.75	4.8	e
5	Piccolo	27	96.3	0.0	3.7	2.56	2.7	e
6	Reflotron	5	80.0	0.0	20.0	3.32	8.5	e*
7	Roche	26	100.0	0.0	0.0	2.32	2.7	e
8	Selectra Pro	13	92.3	0.0	7.7	2.35	5.3	e
9	Siemens	7	100.0	0.0	0.0	2.30	3.4	e
10	Spotchem D-Concept	440	98.0	0.0	2.0	1.45	5.2	e
11	Spotchem SP-4430	83	97.6	0.0	2.4	1.43	4.2	e
12	Cholestech LDX	280	98.9	1.1	0.0	2.26	4.7	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Lithium



QUALAB tolerance : 15 %

Lithium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas Integra 800/40	4	100.0	0.0	0.0	1.11	4.4	e*
2	Other methods	19	100.0	0.0	0.0	1.12	4.4	e

Lactate



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	20	100.0	0.0	0.0	2.34	4.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

HbA1c sample A



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	7.9	2.2	e
2	Roche, Cobas	17	100.0	0.0	0.0	7.9	3.1	e
3	HPLC	9	100.0	0.0	0.0	7.9	2.4	e
4	Afinion	508	98.6	0.8	0.6	7.8	2.8	e
5	Cobas b101	197	95.5	2.5	2.0	7.4	4.2	e
6	DCA2000/Vantage	129	94.5	1.6	3.9	7.8	3.3	e
7	Celltac chemi	19	100.0	0.0	0.0	7.4	3.6	e
8	NycoCard	8	87.5	0.0	12.5	8.0	4.2	e*
9	Eurolyser	9	100.0	0.0	0.0	8.0	3.4	e*
10	A1c Now	217	85.2	11.1	3.7	7.2	5.6	e
11	AFIAS	97	82.5	10.3	7.2	7.2	5.9	e
12	Others	21	90.5	0.0	9.5	7.8	3.1	e
13	Spinit	14	78.6	0.0	21.4	8.0	4.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	6.0	1.5	e
2	Roche, Cobas	18	100.0	0.0	0.0	6.0	3.9	e
3	HPLC	9	100.0	0.0	0.0	6.0	2.9	e
4	Afinion	790	99.4	0.5	0.1	5.9	2.7	e
5	Cobas b101	199	96.5	1.5	2.0	5.7	3.5	e
6	DCA2000/Vantage	192	98.5	0.5	1.0	6.1	3.1	e
7	Celltac chemi	15	100.0	0.0	0.0	5.5	2.6	e
8	NycoCard	6	50.0	50.0	0.0	6.1	3.2	a
9	Eurolyser	5	80.0	20.0	0.0	6.1	6.0	a
10	A1c Now	8	100.0	0.0	0.0	5.6	4.1	e*
11	AFIAS	146	91.1	4.8	4.1	5.8	5.1	e
12	Spinit	10	100.0	0.0	0.0	6.0	5.1	e*
13	Others	15	93.3	0.0	6.7	5.9	3.4	e
14	Quick Read go	5	100.0	0.0	0.0	6.1	4.1	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)

pCO2



QUALAB tolerance : 12 %

pCO2 (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	107	98.1	0.0	1.9	5.36	2.6	e
2	ABL80 FLEX CO-OX / O	5	80.0	20.0	0.0	6.01	6.9	e*
3	ABL90 FLEX / PLUS	115	99.1	0.0	0.9	5.57	2.0	e
4	Cobas b 123	15	100.0	0.0	0.0	5.60	1.5	e
5	Cobas b 221	7	100.0	0.0	0.0	5.72	2.4	e
6	GEM	8	100.0	0.0	0.0	5.70	1.1	e
7	iStat	44	97.7	0.0	2.3	4.81	3.0	e
8	EPOC	54	92.5	5.6	1.9	5.28	4.7	e
9	IL	4	100.0	0.0	0.0	5.70	0.0	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

pO2



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	106	95.3	0.9	3.8	14.60	3.9	e
2	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	14.26	8.2	e*
3	ABL90 FLEX / PLUS	116	95.7	0.9	3.4	13.56	3.8	e
4	Cobas b 123	17	100.0	0.0	0.0	14.37	4.3	e
5	Cobas b 221	4	100.0	0.0	0.0	16.30	3.9	e*
6	GEM	8	100.0	0.0	0.0	14.50	2.6	e
7	iStat	41	95.1	0.0	4.9	15.92	6.4	e
8	EPOC	54	92.5	1.9	5.6	14.79	6.5	e
9	IL	4	100.0	0.0	0.0	14.60	3.7	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)

pH



QUALAB tolerance : 1 %

pH ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	107	98.2	0.9	0.9	7.39	0.1	e
2	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	7.37	0.1	e
3	ABL90 FLEX / PLUS	116	99.1	0.9	0.0	7.40	0.1	e
4	Cobas b 123	16	100.0	0.0	0.0	7.41	0.1	e
5	Cobas b 221	7	100.0	0.0	0.0	7.40	0.1	e
6	GEM	8	100.0	0.0	0.0	7.40	0.1	e
7	iStat	45	97.8	0.0	2.2	7.43	0.1	e
8	EPOC	53	98.1	0.0	1.9	7.39	0.2	e
9	IL	5	100.0	0.0	0.0	7.42	0.1	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose BG



QUALAB tolerance : 9 %

Glucose BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	4	100.0	0.0	0.0	5.8	2.8	e*
2	Cobas b 123	10	90.0	10.0	0.0	5.3	4.8	e*
3	iStat	10	100.0	0.0	0.0	5.4	2.0	e
4	EPOC	42	95.2	0.0	4.8	5.6	3.2	e
5	ABL700/800	98	100.0	0.0	0.0	5.7	1.9	e
6	ABL90 FLEX / PLUS	102	100.0	0.0	0.0	5.6	1.8	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	98	100.0	0.0	0.0	128.0	1.5	e
2	ABL90 FLEX / PLUS	103	98.1	0.0	1.9	128.1	0.4	e
3	ABL80 FLEX CO-OX / O	6	100.0	0.0	0.0	126.5	1.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Potassium BG



QUALAB tolerance : 6 %

Potassium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	3.7	1.5	e
2	Cobas b 123	20	100.0	0.0	0.0	3.7	1.2	e
3	iStat	17	100.0	0.0	0.0	3.8	0.7	e
4	EPOC	46	97.8	0.0	2.2	3.6	1.8	e
5	ABL700/800	99	100.0	0.0	0.0	3.8	1.2	e
6	ABL90 FLEX / PLUS	110	100.0	0.0	0.0	3.7	1.1	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	138.0	0.4	e
2	Cobas b 123	20	100.0	0.0	0.0	138.5	0.6	e
3	iStat	17	100.0	0.0	0.0	142.5	0.4	e
4	EPOC	44	100.0	0.0	0.0	141.0	0.9	e
5	ABL700/800	98	100.0	0.0	0.0	140.8	0.7	e
6	ABL90 FLEX / PLUS	109	100.0	0.0	0.0	141.2	0.3	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Chlorid-BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 123	9	100.0	0.0	0.0	100.5	1.0	e
2	EPOC	15	93.3	0.0	6.7	100.8	0.8	e
3	ABL700/800	93	96.7	2.2	1.1	98.0	1.5	e
4	ABL90 FLEX / PLUS	103	100.0	0.0	0.0	97.0	0.3	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium-BG



MQ tolerance : 12 %
(< 2.00: +/- 0.24 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	0.43	1.0	e
2	Cobas b123	12	100.0	0.0	0.0	0.38	17.9	e*
3	Roche, Cobas	7	100.0	0.0	0.0	0.45	15.7	e*
4	iStat	13	100.0	0.0	0.0	0.48	1.1	e
5	EPOC	40	97.5	0.0	2.5	0.50	5.3	e
6	ABL700/800	98	100.0	0.0	0.0	0.53	2.9	e
7	ABL90 FLEX / PLUS	107	100.0	0.0	0.0	0.52	0.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

FHHb



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	9	100.0	0.0	0.0	3.000	4.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate-BG



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	1.90	4.5	e
2	Cobas b123	8	100.0	0.0	0.0	1.95	2.7	e
3	Roche, Cobas	6	100.0	0.0	0.0	1.90	3.6	e
4	IL	4	100.0	0.0	0.0	1.70	4.8	e*
5	EPOC	40	95.0	0.0	5.0	1.83	2.6	e
6	iStat	15	100.0	0.0	0.0	1.62	2.2	e
7	ABL700/800	100	100.0	0.0	0.0	1.69	4.3	e
8	ABL90 FLEX / PLUS	110	100.0	0.0	0.0	1.59	3.3	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

sO2 OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	15	93.3	0.0	6.7	98.929	0.3	e
2	ABL700/800	88	100.0	0.0	0.0	96.843	0.2	e
3	ABL90 FLEX / PLUS	94	100.0	0.0	0.0	96.917	0.1	e
4	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	96.850	0.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

FO2Hb OR



MQ tolerance : 20 %

FO2Hb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	86	100.0	0.0	0.0	92.364	0.8	e
2	ABL90 FLEX / PLUS	95	100.0	0.0	0.0	92.165	0.1	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	92.100	0.1	e

FCOHb OR



MQ tolerance : 20 %

FCOHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	92.1	6.8	1.1	2.743	10.8	e
2	ABL90 FLEX / PLUS	95	98.9	1.1	0.0	2.901	6.0	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	2.800	7.3	e*

FMetHb OR



MQ tolerance : 20 %

FMetHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	98.9	0.0	1.1	1.992	5.3	e
2	ABL90 FLEX / PLUS	95	98.9	0.0	1.1	2.020	4.3	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	2.100	2.4	e

FHbF OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	40	100.0	0.0	0.0	77.725	3.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin OR



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	6	100.0	0.0	0.0	294.5	2.6	e
2	ABL90 FLEX / PLUS	32	100.0	0.0	0.0	295.8	0.4	e

Troponin I



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	15	100.0	0.0	0.0	6118.8	9.0	e
2	Vidas	12	100.0	0.0	0.0	13629.9	7.2	e
3	Architect High Sensi	10	100.0	0.0	0.0	1363.8	6.9	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Troponin T



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas hs	9	100.0	0.0	0.0	892.00	7.9	e
2	Cobas hs STAT	12	100.0	0.0	0.0	871.18	5.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Myoglobin



QUALAB tolerance : 30 %

Myoglobin (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	123.5	0.7	e
2	Abbott	5	100.0	0.0	0.0	168.0	7.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CK-MB mass



MQ tolerance : 40 %

CK-MB mass (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	9	100.0	0.0	0.0	25.6	3.0	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	860.3	10.2	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-proBNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	11	90.9	9.1	0.0	4234.5	16.9	e*
2	AQT 90 FLEX	4	100.0	0.0	0.0	2825.0	4.8	e
3	VIDAS	9	100.0	0.0	0.0	1179.0	10.3	e*
4	Cobas E / Elecsys	19	100.0	0.0	0.0	1160.7	5.8	e
5	Abbott	9	100.0	0.0	0.0	1531.0	9.1	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

TSH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	24	100.0	0.0	0.0	6.60	3.6	e
2	Abbott	11	100.0	0.0	0.0	5.37	4.7	e
3	VIDAS	14	100.0	0.0	0.0	7.27	5.8	e
4	Dimension	5	100.0	0.0	0.0	5.76	5.4	e*
5	AFIAS	16	74.9	18.8	6.3	9.54	14.2	e*
6	Other methods	5	100.0	0.0	0.0	6.41	8.5	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

T3



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	2.9	3.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

T4



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	152	4.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

FT3



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	21	100.0	0.0	0.0	12.0	3.3	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	12.3	11.4	e*
3	Abbott	10	100.0	0.0	0.0	9.9	4.2	e
4	VIDAS	7	100.0	0.0	0.0	11.7	8.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FT4



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	22	100.0	0.0	0.0	41.0	3.6	e
2	Abbott	11	100.0	0.0	0.0	27.1	6.4	e
3	VIDAS	9	100.0	0.0	0.0	43.1	6.2	e
4	Other methods	8	100.0	0.0	0.0	35.9	3.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Testosterone



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	11	100.0	0.0	0.0	14.3	2.8	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	13.7	6.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Estradiol



QUALAB tolerance : 30 %

Estradiol (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	1190	3.8	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	1877	5.2	e
3	all Participants	4	100.0	0.0	0.0	1157	7.7	e*
4	Abbott	6	100.0	0.0	0.0	1100	2.0	e

SHBG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	15	100.0	0.0	0.0	32.3	4.2	e
2	Abbott	5	100.0	0.0	0.0	33.4	6.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Cortisol



QUALAB tolerance : 20 %

Cortisol (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	19	100.0	0.0	0.0	512	2.8	e
2	Abbott	5	100.0	0.0	0.0	480	5.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Progesteron



MQ tolerance : 30 %

Progesteron (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	100.0	0.0	0.0	38.0	3.4	e
2	Abbott	5	100.0	0.0	0.0	28.7	6.0	e
3	Other methods	4	100.0	0.0	0.0	36.9	9.9	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

DHEAS



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	11	100.0	0.0	0.0	5.84	4.1	e
2	Abbott	4	100.0	0.0	0.0	5.07	7.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Luteinizing hormone



QUALAB tolerance : 24 %

Luteinizing hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	23.0	2.5	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	18.3	6.1	e
3	Abbott	6	100.0	0.0	0.0	14.5	6.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Follicle-stimulating hormone



QUALAB tolerance : 24 %

Follicle-stimulating hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	10	100.0	0.0	0.0	17.1	3.3	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	17.5	9.1	e*
3	Architect	7	100.0	0.0	0.0	17.2	4.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Prolactine



QUALAB tolerance : 24 %

Prolactine (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	13.0	3.7	e
2	Cobas/Roche	11	100.0	0.0	0.0	22.0	3.6	e
3	Abbott	5	100.0	0.0	0.0	18.3	9.2	e*

Insulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	14	100.0	0.0	0.0	502	3.1	e
2	Abbott	4	100.0	0.0	0.0	408	3.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

HGH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	11.97	2.6	e
2	Liaison	4	100.0	0.0	0.0	10.30	5.0	e

IGF-1



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	7	100.0	0.0	0.0	111	11.1	e*
2	Other methods	5	100.0	0.0	0.0	74	3.8	e

Troponin T CR



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1182	93.7	4.8	1.5	314.27	11.9	e

D-dimer CR



QUALAB tolerance : 21 %

D-dimer CR (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1196	81.0	13.5	5.5	0.83	13.8	e
2	Lumira Dx	8	100.0	0.0	0.0	0.72	7.5	e*

CKMB- K8



MQ tolerance : 40 %

CKMB- K8 (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	8	100.0	0.0	0.0	25.1	5.8	e

NT-proBNP CR



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	751	91.7	6.4	1.9	346	14.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

PCO2 CCA



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	100.0	0.0	0.0	9.54	4.9	e*

PO2 CCA



QUALAB tolerance : 15 %

PO2 CCA (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	90.9	0.0	9.1	9.31	4.4	e

pH CCA



QUALAB tolerance : 1 %

pH CCA ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	10	100.0	0.0	0.0	7.14	0.3	e

Potassium CCA



QUALAB tolerance : 6 %
(< 3.3: +/- 0.2 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	5	80.0	0.0	20.0	2.9	0.5	e

Sodium CCA



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	4	75.0	0.0	25.0	127.4	0.5	e

Ferritin



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dimension	5	100.0	0.0	0.0	99.40	5.3	e
2	Beckman	5	100.0	0.0	0.0	74.90	4.7	e
3	all Participants	4	75.0	0.0	25.0	91.20	12.6	e*
4	Cobas E / Elecsys	26	100.0	0.0	0.0	95.25	4.9	e
5	Abbott	13	100.0	0.0	0.0	122.40	5.9	e
6	Mini Vidas	7	71.4	28.6	0.0	70.00	17.2	e*
7	AFIAS	26	100.0	0.0	0.0	78.14	7.2	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Vitamin B12



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	291.00	10.3	e*
2	Cobas E / Elecsys	19	94.7	0.0	5.3	309.79	5.4	e
3	Abbott	11	100.0	0.0	0.0	277.04	7.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Folate



QUALAB tolerance : 24 %
(< 10.00: +/- 2.40 nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	21	100.0	0.0	0.0	9.26	9.9	e
2	Abbott	10	100.0	0.0	0.0	13.32	5.2	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Holotranscobalamine



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	93.7	6.3	0.0	111.0	20.0	a
2	Cobas	30	100.0	0.0	0.0	83.1	6.7	e

Bilirubin total Neo



QUALAB tolerance : 18 %

Bilirubin total Neo (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	227	4.6	e
2	Dimension	5	100.0	0.0	0.0	269	4.0	e

Bilirubin direct



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	133	6.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin neonatal



QUALAB tolerance : 18 %

Bilirubin neonatal (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	9	100.0	0.0	0.0	268	3.0	e
2	Other methods	13	100.0	0.0	0.0	288	3.4	e

PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	18	100.0	0.0	0.0	8.57	6.0	e
2	Abbott	7	100.0	0.0	0.0	8.52	7.4	e*
3	AFIAS	12	91.7	0.0	8.3	8.81	7.2	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

free PSA



QUALAB tolerance : 21 %

free PSA (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	10	100.0	0.0	0.0	2.34	4.6	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	2.59	18.0	e*
3	Abbott	5	100.0	0.0	0.0	2.86	3.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CEA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	12	100.0	0.0	0.0	7.5	5.1	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	8.8	13.2	a
3	Abbott	6	100.0	0.0	0.0	10.8	3.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 125



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	70.0	4.3	e
2	Abbott	5	100.0	0.0	0.0	117.0	5.6	a

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 19-9



MQ tolerance : 25 %

CA 19-9 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	7	100.0	0.0	0.0	17.4	3.9	a
2	ADVIA Centaur XP	4	100.0	0.0	0.0	38.6	13.1	a

6 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 15-3



MQ tolerance : 25 %

CA 15-3 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	10	100.0	0.0	0.0	33.5	2.9	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	45.9	11.6	a
3	Abbott	5	100.0	0.0	0.0	41.5	3.5	a

4 additional results were submitted but not published because the method groups were too small. (< results per group)

AFP



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	86.5	10.3	e*
2	Abbott	4	100.0	0.0	0.0	80.6	3.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG qn



QUALAB tolerance : 25 %

HCG qn (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	13	100.0	0.0	0.0	125.0	3.1	a
2	VIDAS	10	100.0	0.0	0.0	48.1	9.9	e*
3	Architect	9	100.0	0.0	0.0	130.6	6.4	e
4	AFIAS	7	100.0	0.0	0.0	180.0	11.7	a

8 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG intact



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	43.4	2.6	e

S100



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	6	100.0	0.0	0.0	1.49	5.3	e

NSE



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	2.4	11.7	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Thyreoglobulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	84.1	4.8	a
2	Other methods	4	100.0	0.0	0.0	95.0	0.8	e

CK-MB



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	24	100.0	0.0	0.0	62.5	4.6	e
2	Cobas/Roche	7	100.0	0.0	0.0	20.0	3.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol PTS



QUALAB tolerance : 10 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	14	50.0	14.3	35.7	3.96	8.0	e*

Cholesterol HDL PTS



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	14	71.4	0.0	28.6	1.32	6.9	e

Triglycerides



QUALAB tolerance : 18 %
(< 1.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	14	92.9	0.0	7.1	0.67	16.0	e*

C-Peptid



MQ tolerance : 25 %

C-Peptid (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	5.43	3.8	e
2	Other methods	5	100.0	0.0	0.0	4.96	2.7	e

ACTH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	19.28	7.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Procalcitonin



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	9	100.0	0.0	0.0	14.80	5.4	e
2	Cobas	12	100.0	0.0	0.0	9.99	5.4	e
3	VIDAS	13	100.0	0.0	0.0	7.97	4.6	e
4	Liaison	5	100.0	0.0	0.0	19.20	10.9	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

EPO



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	116.4	8.4	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Parathyroid hormone



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas PTH STAT	10	100.0	0.0	0.0	17.0	6.8	e
2	Cobas	10	100.0	0.0	0.0	14.0	8.8	e
3	Abbott	5	100.0	0.0	0.0	31.5	8.5	a

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	21	100.0	0.0	0.0	370	1.6	e

Potassium-K22



QUALAB tolerance : 6 %

Potassium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	3.7	2.0	e

Sodium-K22



QUALAB tolerance : 6 %

Sodium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	146	1.1	e

Glucose-K22



QUALAB tolerance : 9 %

Glucose-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	4.5	3.3	e

Urea-K22



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	4.3	8.2	e*

Osmotic Gap



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Formel 1 (2Na+K+Glu+	10	100.0	0.0	0.0	67.9	11.0	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Digoxin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	9	100.0	0.0	0.0	1.50	7.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Phenytoin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	35	2.5	e

Phenobarbital



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	91	9.2	e*

Vancomycin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	8.3	2.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Valproat



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	359.0	5.5	e

Carbamazepin



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	26.8	3.8	e

Cystatin C



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	17	94.1	0.0	5.9	1.78	5.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Ethanol



QUALAB tolerance : 18 %

Ethanol (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Others	5	80.0	20.0	0.0	14.3	15.9	e*
2	Abbott	7	100.0	0.0	0.0	15.3	6.2	e*
3	Roche, Cobas	19	100.0	0.0	0.0	15.0	5.1	e

Ammonia



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	93.5	10.9	e*
2	all Participants	6	100.0	0.0	0.0	117.0	2.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Calprotectin



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Bühlmann fCALturbo	21	90.4	4.8	4.8	497	14.5	e
2	Bühlmann Quantum Blu	5	100.0	0.0	0.0	542	24.8	a
3	Liaison	20	95.0	5.0	0.0	216	13.4	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total Af/b101



QUALAB tolerance : 10 %

Cholesterol total Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	304	99.3	0.0	0.7	4.99	3.0	e
2	Afinion	417	98.6	0.2	1.2	4.93	3.5	e

Cholesterol HDL Af/b101



QUALAB tolerance : 21 %

Cholesterol HDL Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	301	91.4	0.0	8.6	0.91	4.1	e
2	Afinion	414	92.5	0.0	7.5	0.88	4.2	e

Tryglycerides Af/b101



QUALAB tolerance : 18 %

Tryglycerides Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	300	99.0	0.0	1.0	1.67	2.3	e
2	Afinion	417	98.8	0.5	0.7	1.62	5.0	e

Troponin I S



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	298	84.6	3.7	11.7	1087.80	10.7	e

D-dimer qn S



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	297	81.8	3.0	15.2	0.91	8.9	e

NT-proBNP S



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	223	48.5	2.2	49.3	2069.2	12.5	e

Homocystein



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	6	100.0	0.0	0.0	31.0	3.6	e
2	all Participants	4	100.0	0.0	0.0	26.6	5.9	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	102.5	9.6	a
2	Beckman	5	100.0	0.0	0.0	96.0	2.9	e
3	Roche	23	100.0	0.0	0.0	101.8	4.9	e
4	Fuji Dri-Chem	170	98.2	1.2	0.6	82.6	5.2	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Bicarbonat



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	26.7	4.1	e*
2	Abbott	4	100.0	0.0	0.0	25.9	3.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholinesterase



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	7.9	7.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose CSF



QUALAB tolerance : 9 %

Glucose CSF (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	3.45	2.4	e
2	Other methods	13	100.0	0.0	0.0	3.38	2.8	e

Lactate CSF



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	1.82	3.9	e
2	Other methods	11	90.9	9.1	0.0	1.79	8.5	e*

Protein CSF



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	15	100.0	0.0	0.0	0.35	4.4	e
2	Other methods	4	100.0	0.0	0.0	0.42	11.4	d

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Albumine CSF



MQ tolerance : 20 %

Albumine CSF (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	212.00	4.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

CDT



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	85.7	14.3	0.0	1.00	9.2	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Tacrolimus



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	8.4	5.0	e

Totalprotein E



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	100.0	0.0	0.0	76.6	4.6	a

Albumin E



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	30	100.0	0.0	0.0	65.1	5.2	a

alpha-1-Globuline



MQ tolerance : 30 %

alpha-1-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	11	100.0	0.0	0.0	1.4	12.7	e*
2	capillary electropho	19	100.0	0.0	0.0	2.7	8.2	e

alpha-2-Globuline



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	30	100.0	0.0	0.0	8.0	13.2	a

beta-Globuline



MQ tolerance : 30 %

beta-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	16	100.0	0.0	0.0	10.8	7.3	e

Beta-1-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	8	87.5	12.5	0.0	6.2	18.2	a

Beta-2-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	7	100.0	0.0	0.0	5.9	10.4	e*

gamma-Globuline



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	7	100.0	0.0	0.0	12.7	8.8	e

Gamma-Globuline+P



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	23	100.0	0.0	0.0	11.6	14.5	e

Beta-Globuline+P



MQ tolerance : 30 %

Beta-Globuline+P (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	6	100.0	0.0	0.0	12.1	14.4	a

Immunfixation



QUALAB tolerance : 1 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Interpretation	25	96.0	0.0	4.0	8	0.0	e

Folate in Erythrocytes



MQ tolerance : 40 %

Folate in Erythrocytes (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	10	100.0	0.0	0.0	143	24.8	a
2	Roche, Cobas	21	90.5	0.0	9.5	972	10.7	e
3	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	473	17.2	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Gallensäure



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	11	81.8	18.2	0.0	11.5	17.4	e*
2	all Participants	16	100.0	0.0	0.0	8.8	8.4	e

BNP



QUALAB tolerance : 27 %
(< 75.0: +/- 20.0 ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	9	100.0	0.0	0.0	20.5	41.1	e*

Troponin Triage



QUALAB tolerance : 24 %

Troponin Triage (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage high sensitiv	95	89.4	5.3	5.3	376.10	13.1	e
2	Triage Next Gen	11	72.7	0.0	27.3	10.00	0.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-pro BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	53	94.3	1.9	3.8	403	12.3	e

D-dimer Triage



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	90	51.1	13.3	35.6	536.50	15.5	e

Vitamin D 25 (OH)



QUALAB tolerance : 27 %

Vitamin D 25 (OH) (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	LCMS	5	100.0	0.0	0.0	111.8	3.6	e
2	Cobas	15	100.0	0.0	0.0	97.8	3.8	e
3	VIDAS	6	100.0	0.0	0.0	113.3	4.0	e
4	Other methods	10	90.0	0.0	10.0	106.8	17.8	a
5	Architect	10	100.0	0.0	0.0	119.1	7.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

AMH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	17.4	5.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Inhibin B



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	83.3	16.7	0.0	160.0	15.4	a

Calcitonin



MQ tolerance : 25 %

Calcitonin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	6.4	3.1	e
2	Other methods	7	100.0	0.0	0.0	22.0	5.9	e

IGF-BP3



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	3.27	3.8	e
2	all Participants	4	75.0	0.0	25.0	3.79	20.1	a

Renin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	7	100.0	0.0	0.0	67.0	5.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti Thyreoglobulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	7	100.0	0.0	0.0	73	7.8	e
2	Cobas	9	100.0	0.0	0.0	360	3.7	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti TPO



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	90	7.6	e
2	Abbott	7	100.0	0.0	0.0	56	4.2	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

TRAK



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	4.17	7.6	e*
2	Roche, Cobas	7	100.0	0.0	0.0	2.00	10.2	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine WB



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	69	84.1	5.8	10.1	205	10.8	e

IL6



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	4504.0	3.6	e

Pankreas Elastase



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	10	100.0	0.0	0.0	164	19.6	e*

Copeptin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Kryptor	7	100.0	0.0	0.0	2.9	16.7	e*

Occult blood qn



MQ tolerance : 30 %

Occult blood qn (ng/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OC-Sensor	7	100.0	0.0	0.0	50	0.0	e

Amylase-Urine



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	4	100.0	0.0	0.0	107	3.3	e

Pancreatic Amylase-Urine



QUALAB tolerance : 18 %
(< 25.0: +/- 5.0 U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	4	100.0	0.0	0.0	4.0	10.0	e*

Calcium-Urine



MQ tolerance : 9 %

Calcium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	2.15	1.9	e
2	Abbott	7	100.0	0.0	0.0	2.02	1.7	e
3	Other methods	7	100.0	0.0	0.0	2.11	3.4	e*

Chloride-Urine



MQ tolerance : 12 %

Chloride-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	10	100.0	0.0	0.0	138	1.0	e
2	Roche, Cobas	11	100.0	0.0	0.0	130	2.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose-Urine



QUALAB tolerance : 9 %

Glucose-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	21	100.0	0.0	0.0	8.1	1.9	e

Magnesium-Urine



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	15	100.0	0.0	0.0	2.55	3.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality-Urine



MQ tolerance : 10 %

Osmolality-Urine (mosm/kg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	19	100.0	0.0	0.0	604	1.2	e

Phosphate-Urine



MQ tolerance : 15 %

Phosphate-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	23	100.0	0.0	0.0	11.6	4.6	e

Potassium-Urine



MQ tolerance : 15 %

Potassium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	32	100.0	0.0	0.0	49	2.8	e

Protein-Urine



QUALAB tolerance : 15 %

Protein-Urine (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	18	100.0	0.0	0.0	323.2	3.5	e
2	Abbott	14	100.0	0.0	0.0	394.1	2.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium-Urine



MQ tolerance : 15 %

Sodium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	32	100.0	0.0	0.0	117	2.4	e

Urea-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	30	100.0	0.0	0.0	202	6.2	e

Uric Acid-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	21	100.0	0.0	0.0	0.78	5.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Specific Gravity-Urine



MQ tolerance : 5 %

Specific Gravity-Urine ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Refractometer	7	100.0	0.0	0.0	1.017	0.1	e

Creatinine U



QUALAB tolerance : 24 %
(< 20.0: +/- 4.8 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	26.0	7.2	e
2	Roche, Cobas	14	100.0	0.0	0.0	24.2	3.2	e
3	Aution	8	100.0	0.0	0.0	10.0	0.0	a
4	AFIAS	20	100.0	0.0	0.0	22.7	12.1	e
5	Afinion	487	93.4	3.5	3.1	22.5	10.4	e
6	Sysmex U	16	87.5	0.0	12.5	24.0	51.9	a
7	Turbidimetry	4	100.0	0.0	0.0	25.3	8.9	e*
8	DCA2000/Vantage	146	94.6	2.7	2.7	23.7	10.2	e
9	Siemens Clinitek	26	96.2	0.0	3.8	24.0	40.3	a

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinin Urin



QUALAB tolerance : 21 %
(< 2.0: +/- 0.4 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	3.2	2.6	e
2	Roche	21	100.0	0.0	0.0	3.4	3.6	e
3	Beckman	4	100.0	0.0	0.0	3.5	7.5	e*
4	Siemens	5	100.0	0.0	0.0	3.0	5.8	e*
5	DCA2000/Vantage	144	93.0	3.5	3.5	3.5	8.0	e
6	Afinion	484	99.4	0.2	0.4	3.0	5.0	e
7	Sysmex U	13	69.2	0.0	30.8	4.4	0.0	e
8	Aution	8	50.0	0.0	50.0	4.4	0.0	e
9	Siemens Clinitek	24	79.2	0.0	20.8	4.4	0.2	e
10	Other methods	4	100.0	0.0	0.0	0.9	0.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)